Microparticles prepared with 50–190 kDa chitosan as promising non-toxic carriers for pulmonary delivery of isoniazid

Oliveira, Paula Martins de; Matos, Breno N.; Pereira, Priscilla Aparecida Tártari; Gratieri, Taís; Faccioli, Lúcia Helena; Cunha-Filho, Marcílio; Gelfuso, Guilherme M.

doi:10.1016/j.carbpol.2017.06.090

Cited by 51 publications

(18 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These advantages include large surface area (100 m 2 ), thin (0.1-0.2 mm) physical barriers for absorption, rich vascularization to provide rapid absorption into blood circulation, absence of extreme pH, avoidance of first-pass metabolism with higher bioavailability, fast systemic delivery from the alveolar region to lung, and less metabolic activity compared to that in the other areas of the body (Ali 2010;Lee et al 2018;Yu et al 2016). The local delivery of drugs using inhalers has been a proper choice for most pulmonary diseases (Pison et al 2006), including asthma (Basheti et al 2017;Lavorini et al 2008), cystic fibrosis (Adi et al 2010;Bilton et al 2011), chronic obstructive pulmonary disease (COPD) (Schulte et al 2008;Sulaiman et al 2017), lung infections (Cipolla and Chan 2013;Golshahi et al 2011;Oliveira et al 2017), lung cancer (Zhu et al 2017), and pulmonary hypertension Kanwar et al 2016). In addition to the local delivery of drugs, inhalation can also be a good platform for the systemic circulation of drugs (Moroz et al 2016;Rytting et al 2008;Thwala et al 2017).…”

Section: Introductionmentioning

confidence: 99%

“…Microparticles (MPs) and nanoparticles (NPs), including micelles (Mahajan and Mahajan 2016), liposomes (Bhardwaj et al 2016), solid lipid NPs (Ji et al 2016), inorganic particles (Seydoux et al 2016), and polymeric particles (Oliveira et al 2017) have been prepared and applied for sustained and/or targeted drug delivery to the lung. Although MPs and NPs were prepared by various natural or synthetic polymers, poly(lactic acid) (PLA) and poly(lactic-co-glycolic acid) (PLGA) particles have been preferably employed owing to their biocompatibility and biodegradability (Kumari et al 2010;Mohamed and van der Walle 2008;Na et al 2007).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Poly(lactic acid)/poly(lactic-co-glycolic acid) particulate carriers for pulmonary drug delivery

Emami

Yazdi

2019

J. Pharm. Investig.

View full text Add to dashboard Cite

Background Pulmonary route is an attractive target for both systemic and local drug delivery, with the advantages of a large surface area, rich blood supply, and absence of first-pass metabolism. Numerous polymeric micro/nanoparticles have been designed and studied for controlled and targeted drug delivery to the lung. Area covered Among the natural and synthetic polymers for polymeric particles, poly(lactic acid) (PLA) and poly(lacticco-glycolic acid) (PLGA) have been widely used for the delivery of anti-cancer agents, anti-inflammatory drugs, vaccines, peptides, and proteins because of their highly biocompatible and biodegradable properties. This review focuses on the characteristics of PLA/PLGA particles as carriers of drugs for efficient delivery to the lung. Furthermore, the manufacturing techniques of the polymeric particles, and their applications for inhalation therapy were discussed. Expert opinion Compared to other carriers including liposomes, PLA/PLGA particles present a high structural integrity providing enhanced stability, higher drug loading, and prolonged drug release. Adequately designed and engineered polymeric particles can contribute to a desirable pulmonary drug delivery characterized by a sustained drug release, prolonged drug action, reduction in the therapeutic dose, and improved patient compliance.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Poly(lactic acid)/poly(lactic-co-glycolic acid) particulate carriers for pulmonary drug delivery

Emami

Yazdi

2019

J. Pharm. Investig.

View full text Add to dashboard Cite

show abstract

“…Moreover, chitosan particles are able to interact with the mannose receptors of macrophages, which results in increased phagocytosis [97]. Chitosan microparticles have been formulated with several anti-TB drugs including rifampicin [71,73,74], rifabutin [74], isoniazid [75,76], ofloxacin [60] and ethionamide [72] for pulmonary delivery. Cross-linked isoniazid loaded chitosan microparticles allowed a more sustained isoniazid release with 50% release in 6 h in comparison to non-crosslinked microparticles with over 50% released in 1 h [76].…”

Section: Chitosanmentioning

confidence: 99%

“…Chitosan microparticles have been formulated with several anti-TB drugs including rifampicin [71,73,74], rifabutin [74], isoniazid [75,76], ofloxacin [60] and ethionamide [72] for pulmonary delivery. Cross-linked isoniazid loaded chitosan microparticles allowed a more sustained isoniazid release with 50% release in 6 h in comparison to non-crosslinked microparticles with over 50% released in 1 h [76]. Both non-and crosslinked microparticles can be of interest for TB treatment because in the first phase of the treatment, which is more intense, non-crosslinked microparticles may rapidly release isoniazid into the alveoli whereas cross-linked microparticles can be used in a second phase of the treatment (maintenance phase).…”

Section: Chitosanmentioning

confidence: 99%

Exploring inhalable polymeric dry powders for anti-tuberculosis drug delivery

Miranda

Rodrigues

Domingues

et al. 2018

Materials Science and Engineering: C

View full text Add to dashboard Cite

The growing interest on polymeric delivery systems for pulmonary administration of drugs anticipates a more direct and efficient treatment of diseases such as tuberculosis (TB) that uses the pulmonary route as the natural route of infection. Polymeric microparticles or nano-in-microparticles offer target delivery of drugs to the lungs and the potential to control and sustain drug release within TB infected macrophages improving the efficiency of the anti-TB treatment and reducing side effects. In a dry powder form these inhalable delivery systems have increased stability and prolonged storage time without requiring refrigeration, besides being cost-effective and patient convenient. Thus, this review aims to compile the recent innovations of inhalable polymeric dry powder systems for the delivery of anti-TB drugs exploring the methods of production, aerodynamic characterization and the efficacy of targeted drug delivery systems using in vitro and in vivo models of the disease. Advanced knowledge and promising outcomes of these systems are anticipated to simplify and revolutionize the pulmonary drug delivery and to contribute towards more effective anti-TB treatments.

show abstract

“…CS has been studied as a coating (Llabot et al, 2011;Lupo et al, 2017) for nanoparticles or has been cross-linked with other materials (Marin Briceño, & Caballero-George, 2013;Oliveira et al, 2017;Rodrigues, Dionísio, López, & Grenha, 2012;Schattling, Taipaleenmäki, Zhang, & Städler, 2017) to increase the mucoadhesive properties of drug carriers to improve bioavailability. Pawar et al have reported on a good mucoadhesion of CS coated particles in the rat gut, which supplements other studies assuring the mucoadhesive properties of CS (Pawar, Asthana, Mishra, Chaurasia, & Chourasia, 2013).…”

Section: Introductionmentioning

confidence: 99%

Development of electrosprayed mucoadhesive chitosan microparticles

Moreno

Mendes

Stephansen

et al. 2018

Carbohydrate Polymers

View full text Add to dashboard Cite

The efficacy of chitosan (CS) to be used as drug delivery carrier has previously been reported. However, limited work has been pursued to produce stable and mucoadhesive CS electrosprayed particles for oral drug delivery, which is the aim of this study. Various CS types with different molecular weight (MW), degree of deacetylation (DD), and degree of polymerization (DP) were assessed. In addition, the effect of the solvent composition was also investigated. Results showed that stable CS electrosprayed particles can be produced by dissolving 3% w/v of low MW CS in mixtures of aqueous acetic acid and ethanol (50/50% v/v). The stable CS particles displayed diameters of approximately 1 μm as determined by dynamic light scattering. The zeta potential of these particles was found to be approximately 40 mV confirming the mucoadhesion properties of these CS electrosprayed particles and its potential to be used as drug delivery carrier.

show abstract

Microparticles prepared with 50–190 kDa chitosan as promising non-toxic carriers for pulmonary delivery of isoniazid

Cited by 51 publications

References 45 publications

Poly(lactic acid)/poly(lactic-co-glycolic acid) particulate carriers for pulmonary drug delivery

Poly(lactic acid)/poly(lactic-co-glycolic acid) particulate carriers for pulmonary drug delivery

Exploring inhalable polymeric dry powders for anti-tuberculosis drug delivery

Development of electrosprayed mucoadhesive chitosan microparticles

Contact Info

Product

Resources

About